Agustsson TT et al (2015) The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study. Eur J Endocrinol 173(5):655–664

Article  CAS  PubMed  Google Scholar 

Daly AF et al (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91(12):4769–4775

Article  CAS  PubMed  Google Scholar 

Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72(3):377–382

Article  PubMed  Google Scholar 

Giustina A, Colao A (2025) Acromegaly N Engl J Med 393(19):1926–1939

Article  CAS  PubMed  Google Scholar 

Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179(4068):77–79. https://doi.org/10.1126/science.179.4068.77

Article  CAS  PubMed  Google Scholar 

Caron PJ et al (2014) Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab 99(4):1282–1290

Article  CAS  PubMed  Google Scholar 

Neggers SJ et al (2015) Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study. Eur J Endocrinol 173(3):313–323

Article  CAS  PubMed  PubMed Central  Google Scholar 

Melmed S et al (2018) A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552–561

Article  PubMed  PubMed Central  Google Scholar 

Melmed S et al (2025) Consensus on acromegaly therapeutic outcomes: an update. Nat Reviews Endocrinol 21(11):718–737

Article  Google Scholar 

Katznelson L et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951

Article  CAS  PubMed  Google Scholar 

Papaioannou C, Druce M (2023) Preoperative medical treatments and surgical approaches for acromegaly: a systematic review. Clin Endocrinol (Oxf) 98(1):14–31

Article  PubMed  Google Scholar 

Fleseriu M et al (2021) A pituitary society update to acromegaly management guidelines. Pituitary 24(1):1–13

Article  PubMed  Google Scholar 

Daly AF et al (2010) Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 95(11):E373–E383

Article  PubMed  Google Scholar 

Rostomyan L et al (2015) Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer 22(5):745–757

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marques P et al (2020) Significant benefits of AIP testing and clinical screening in familial isolated and young-onset pituitary tumors. J Clin Endocrinol Metab 105(6):e2247–e2260

Article  PubMed  PubMed Central  Google Scholar 

Chahal HS et al (2012) Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab 97(8):E1411–E1420

Article  CAS  PubMed  Google Scholar 

Tuominen I et al (2015) AIP inactivation leads to pituitary tumorigenesis through defective Galphai-cAMP signaling. Oncogene 34(9):1174–1184

Article  CAS  PubMed  Google Scholar 

Ritvonen E et al (2017) Impact of AIP and inhibitory G protein alpha 2 proteins on clinical features of sporadic GH-secreting pituitary adenomas. Eur J Endocrinol 176(2):243–252

Article  CAS  PubMed  Google Scholar 

Bogner EM et al (2020) miR-34a is upregulated in AIP-mutated somatotropinomas and promotes octreotide resistance. Int J Cancer 147(12):3523–3538

Article  CAS  PubMed  Google Scholar 

Denes J et al (2015) Regulation of aryl hydrocarbon receptor interacting protein (AIP) protein expression by MiR-34a in sporadic somatotropinomas. PLoS ONE 10(2):e0117107

Article  PubMed  PubMed Central  Google Scholar 

de Kasuki J, PL et al (2011) Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. Neuroendocrinology 94(1):39–48

Article  Google Scholar 

Kasuki L et al (2012) AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr Relat Cancer 19(3):L25–L29

Article  CAS  PubMed  Google Scholar 

Korbonits M et al (2024) Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 2, specific diseases. Nat Rev Endocrinol 20(5):290–309

Article  PubMed  Google Scholar 

Bonneville F et al (2019) MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: PRIMARYS post hoc analysis. Eur J Endocrinol 180(3):155–164

Article  CAS  Google Scholar 

Lucas T et al (2003) Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf) 58(4):471–481

Article  CAS  PubMed  Google Scholar 

Jaffrain-Rea ML et al (2013) Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. Endocr Relat Cancer 20(5):753–766

Article  CAS  PubMed  Google Scholar 

Chahal HS et al (2011) Somatostatin analogue treatment increases AIP protein expression in somatotroph tumours from patients with acromegaly and in GH3 cells in vitro. in Horm Res Paediatr 76(Suppl. 1), pp. 111–112

Potorac I et al (2015) Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr Relat Cancer 22(2):169–177

Article  CAS  PubMed  Google Scholar 

Potorac I et al (2016) T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocr Relat Cancer 23(11):871–881

Article  PubMed  Google Scholar 

Puig-Domingo M et al (2010) Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab 95(11):4973–4978

Article  CAS  PubMed  Google Scholar 

Heck A et al (2012) Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol (Oxf) 77(1):72–78

Article  CAS  PubMed  Google Scholar 

Heck A et al (2016) Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine 52(2):333–343

Article  CAS  PubMed  Google Scholar 

Heck A et al (2016) MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly. Endocrine 53(1):327–330

Article  CAS  PubMed  Google Scholar 

Yang C et al (2019) Preoperative Somatostatin Analogues in Patients with Newly-diagnosed Acromegaly: A Systematic Review and Meta-analysis of Comparative Studies. Sci Rep 9(1):14070

Article  PubMed  PubMed Central